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Abstract. Background: High-dose chemotherapy (HDC)
followed by autologous stem cell transplantation (ASCT) is
used for the treatment of hemato-oncologic malignancies. In
this study, we measured the effect of HDC/ASCT on plasma
concentrations of antiangiogenic soluble vascular endothelial
growth factor receptor 1 (sVEGFR1) and of leukapheresis
products (LP) and patient serum on chick chorioallantoic
(CAM) angiogenesis. Materials and Methods: VEGFR1- and
CD34-expressing cells of leukapheresis products were
analyzed by flow cytometry. Alternatively spliced isoforms of
VEGFR1 mRNA were quantified using reverse transcription
PCR. Results: Plasma concentrations of sVEGFR1 decreased
after HDC, but significantly increased after ASCT. In the
CAM assay, sera of patients elicited a proangiogenic effect
before and after HDC, but a strong antiangiogenic response
after ASCT, comparable to that of bevacizumab at therapeutic
concentrations. LP contains high concentrations of
sVEGFR1, and high density of VEGFR1+ neutrophilic
granulocytes, in which mRNA expression is shifted toward the
soluble VEGFR1 isoform. Conclusion: Neutrophil-derived
antiangiogenic sVEGFR1 within the LP may contribute to the
therapeutic efficacy of ASCT.
Autologous stem cell transplantation (ASCT) after high-dose
chemotherapy (HDC) emerged as a treatment option for
hematologic and oncologic malignancies more than fifty years
ago (1) and represents the cornerstone for the first-line treatment
of younger patients with multiple myeloma (2). It is an accepted
therapeutic option in refractory or relapsed lymphoma (3),
relapsed testicular cancer (4), and some forms of leukemia (5).
ASCT has also been used for therapeutic angiogenesis in
non-oncologic disease, such as ischemic cardiac (6-8)  and
limb (9) disease, and connective tissue disorders (10-12) in
order to improve microcirculation, although randomized
controlled trials in ischemic cardiovascular disease reported
conflicting data on its beneficial effects (6-8). However, there
is considerable heterogeneity in the methods of mobilization,
collection, and storage of autologous stem cells.
While there is evidence that autologous bone marrow cell
transplantation has proangiogenic effects in the treatment of
ischemic disease (10, 13-15), only little is known about the
angiogenic potential of ASCT after HDC in the treatment of
hematologic and oncologic malignancies (16-19).
Physiological and pathological angiogenesis, including
tumor angiogenesis, is regulated by a balance of pro- and
antiangiogenic molecules. When the balance shifts in favor of
angiogenesis inducers, an angiogenic switch activates the
normally quiescent vasculature to form new blood vessels
(20). Even a short-lived, transient angiogenic switch can prime
progressive tumor growth (21). A prominent proangiogenic
signaling circuit involves members of the vascular endothelial
growth factor (VEGF) family, in particular VEGFA, and its
receptors, VEGFR2 and VEGFR3 (22). VEGFR1, a receptor
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of VEGFA and placental growth factor (PGF), has strong
antiangiogenic activity and its genetic ablation has been shown
to be associated with excessive angiogenesis (23). PGF has
been shown to act as an amplifier of VEGF-driven
angiogenesis (24). Besides being expressed on endothelial
cells (25), VEGFR1 is also expressed on a variety of other cell
types, including neutrophils (26, 27). Two different isoforms
of VEGFR1 arise through alternative splicing: a full-length
transmembrane protein containing an intracellular tyrosine
kinase domain, and a truncated soluble form, lacking the
transmembrane and tyrosine kinase domains (sVEGFR1) (25).
Proteolytic cleavage of VEGFR1 may also be involved in the
generation of sVEGFR-1 (28). VEGFR1 and sVEGFR1 both
exert antiangiogenic effects by sequestration of VEGF, and
through a dominant negative effect by forming heterodimers
with VEGFR1 and -2 (29).
The aim of this study was to determine the effect of HDC
and ASCT on plasma concentrations of sVEGFR1, VEGF, and
PGF and on angiogenesis.
Materials and Methods
Patients, blood samples, leukapheresis products, and peripheral blood
mononuclear cells. Patients undergoing HDC and ASCT for the
treatment of various cancer types were included in the study. The
study protocol was approved by the local Ethics Commission
(University of Zurich approval number EK-1363) and written
informed consent was obtained from all patients. Patient
characteristics are shown in Table I. Serum and EDTA plasma
samples were taken 6 h before HDC, 4 h before ASCT, 15 min after
ASCT, and at the time of hematological reconstitution (neutrophil
count ≥500/μl). Following stem cell mobilizing chemotherapy and
stimulation with granulocyte-colony stimulating factor (G-CSF),
leukapheresis products were collected, supplemented with 10%
dimethyl sulfoxide (DMSO) and 33% RPMI cell culture medium and
stored in liquid nitrogen until ASCT. For analysis of the leukapheresis
products, leukocytes were separated from the leukapheresis product
by Ficoll gradient centrifugation, washed three times with phosphate
buffered saline (PBS)/5 mM EDTA and filtered through a 100 μm cell
strainer. Peripheral blood mononuclear cells (PBMCs) were collected
from the blood of cancer patients by Ficoll gradient centrifugation. 
Quantification of VEGFR1, VEGF, and PGF protein expression by
enzyme-linked immunosorbent assay (ELISA). ELISA for the
quantification of VEGFR1, VEGF, and PGF were performed using
immunoassays from R&D Systems (Abingdon, UK), and
concentrations in plasma and supernatants/medium expressed as pg/ml,
or as pg/mg total protein for VEGFR1 concentrations in cell lysates.
Chick chorioallantoic membrane (CAM) assay for the analysis of
angiogenesis. The CAM from a shell-less chick embryo culture was
used as described earlier (30). In brief, chicken egg contents with intact
yolk and embryo were incubated at 37˚C and 70% humidity.
Methylcellulose disks (usually about 4-7 per CAM) as carriers for test
samples were placed on the CAM of day 8.5 chick embryos in
duplicates and inoculated with 10 μl of serum (± bevacizumab),
leukapheresis product, or freezing medium containing DMSO.
Bevacizumab (BV) was used at a final concentration of 500 μg/ml.
Angiogenesis was compared by stereomicroscopy between non-
inoculated CAM areas and areas inoculated with the appropriate control
probes after 48 h, following the application of 20% intralipid (Fresenius
Kabi, Uppsala, Sweden) underneath the intact CAM to enhance the
vascular contrast, and scored by two independent investigators blinded
to the experiments: 0, neutral; (+), weak stimulation; +, marked
stimulation; ++, strong stimulation; (–), weak inhibition; –, marked
inhibition; – –, strong inhibition of vasculogenesis (31). Sera from
healthy volunteers were used for comparison.
Magnetic activated cell sorting (MACS) for the separation of CD34-
and VEGFR1- positive and negative cells from leukapheresis products.
Leukocytes from leukapheresis products were positively selected for
CD34+ cells using the CD34 MicroBead Kit according to the
manufacturer’s protocol (Miltenyi Biotech, Bergisch Gladbach,
Germany) and for VEGFR1+ cells using an allophycocyanin (APC)-
labeled monoclonal mouse-anti-human VEGFR1 antibody (R&D
Systems) and anti-APC beads (Miltenyi Biotech).
Reverse transcription quantitative PCR (RT-qPCR) for quantification
of the alternatively spliced isoforms of VEGFR1 mRNA. RT-qPCR
was performed for the quantification of the alternatively spliced
mRNA isoforms of sVEGFR1 and transmembrane VEGFR1 from
snap frozen cells after removal of genomic DNA in an ABI PRISM
7700 Sequence Detector (Applied Biosystems Inc., Foster City, CA,
USA) for 40 cycles. Sequences of primers and fluorescent VIC-
labeled probes were: sVEGFR1, 5’ TGTTGCAGTGCTCAC
CTCTGATTGTAATTTCTT 3’ (probe), 5’ GCAAGATTCAGGCAC
Table I. Patient characteristics.
Patient number Gender Diagnosis Chemotherapy (conditioning regimen) Dexamethasone* G-CSF†
1 Female Multiple myeloma Melphalan Yes No
2 Male T-Cell lymphoma, relapsed BEAM Yes Yes
3 Female Hodgkin lymphoma, relapsed BEAM Yes Yes
4 Female Multiple myeloma Melphalan Yes Yes
5 Female AML M5 Busulfan/Cyclophosphamide No Yes
6 Male Multiple myeloma Melphalan Yes Yes
7 Female Multiple myeloma Melphalan Yes Yes
*Given during and/or after chemotherapy. †Given before autologous stem cell transplantation. BEAM: Carmustine (BiCNU), etoposide, cytarabine
(arabinoside), melphalan; AML: acute myeloid leukemia; G-CSF: granulocyte-colony stimulating factor.
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CTATGC 3’ (sense), 5’ AGATCCGAGAG AAAACAGCCTTT 3’
(antisense); VEGFR1, 5’ TGCTTCCTGATCTCTGATTGTAATTTCT
TTCTTCTG 3’ (probe), 5’ GCAAG ATTCAGGCACCTATGC 3’
(sense), 5’ CTGAGGTTTCGCA GGAGGTATG 3’ (antisense). 
Analysis of full blood counts and leukocyte subfractions with blood
cell analyzer and cytologic staining. Full blood counts from EDTA
plasma and leukocyte subfractions from leukapheresis products, and
CD34 and VEGFR1 positively and negatively selected cells were
analyzed using an automated blood cell analyzer (ADVIA 120;
Siemens, Erlangen, Germany) and by cytologic staining of cytospins
with May-Grünwald-Giemsa.
Flow cytometric analysis for the analysis of CD34+ and VEGFR1+
cells. Leukapheresis products, and CD34 and VEGFR1 positively and
negatively selected cells of leukapheresis products were stained with
Figure 1. Enzyme-linked immunosorbent assays for the analysis of plasma concentrations of vascular endothelial growth factor receptor-1 (VEGFR1)
(a, percentage change; b, plasma concentration), vascular endothelial growth factor (VEGF) (c), and placental growth factor (PGF) (d) in seven
patients. *p<0.05.
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a fluorescein isothiocyanate (FITC)-labeled monoclonal mouse-anti-
human CD34 antibody (Miltenyi Biotech) and an APC-labeled
monoclonal mouse-anti-human VEGFR1 antibody (R&D Systems)
and subjected to flow cytometric analysis using a FACSCalibur® flow
cytometer, CellQuestPro (Becton Dickinson Biosciences, Franklin
Lakes, NJ, USA), and WinMDI Version 2.9 software (Joseph Trotter,
Scripps Research Institute, La Jolla, CA, USA).
Statistics. Kruskal-Wallis and Mann-Whitney U-tests were applied to
assess statistical significance (P) of the difference between multiple
and two groups, respectively. Fisher’s r to Z test was performed for
the calculation of significance P of correlations. P<0.05 was
considered significant.
Results
Plasma VEGFR1 decreased after HDC, but significantly
increased after ASCT. Plasma PGF, but not VEGF, increased
after HDC. Median plasma VEGFR1 levels decreased by 13%
after HDC, but increased by 33% immediately after ASCT. This
increase was still apparent after hematological reconstitution 11
days after ASCT (Figure 1a and b). Changes in VEGF
concentrations were not significant at any time point (Figure 1c).
In contrast, PGF concentrations significantly increased after
HDC, but did not further increase after ASCT (Figure 1d). 
Sera of patients before HDC and ASCT stimulate
angiogenesis, while sera after ASCT and leukapheresis
products inhibit angiogenesis. Sera from patients undergoing
HDC and ASCT induced increased capillary growth and
numbers of bifurcations in the CAM assay before HDC, and
after HDC/before ASCT. After ASCT, sera exhibited less
ability to induce capillary growth and bifurcations, which was
sustained through the time of hematological reconstitution 11
days later. Overall, the inhibitory effect of ASCT on
angiogenesis in the CAM assay was comparable to the effect
of bevacizumab, a humanized mouse monoclonal antibody
targeting VEGF, when added to serum obtained before ASCT
in a concentration in the upper range measured in human
serum during clinical trials with weekly administration of
bevacizumab at therapeutical doses of 10 mg/kg body weight.
Supernatants of leukapheresis products had strong
antiangiogenic effects, whereas sera of healthy volunteers, or
freezing medium only, containing 10% DMSO, did not have
any measurable effect on CAM angiogenesis (Figure 2a and
b). Intra-individual increases in plasma VEGFR1
concentrations were negatively associated with angiogenesis,
whereas decreases were positively associated. This correlation
was statistically significant (Figure 3).
Leukapheresis products contain high concentrations of
sVEGFR1 and VEGFR1 is expressed mostly on CD34– cells.
To test the hypothesis that elevated levels of sVEGFR1 may
be due to the sVEGFR1 present in the leukapheresis product,
Figure 2. Chick chorioallantoic membrane (CAM) assays (magnification ×12.5) with semi-quantitative angiogenesis scores at the bottom of each photograph
(a) and bar charts with semi-quantitative angiogenesis scores of CAM duplicates, based on the number of bifurcations which are compared between the
center and outside of the methylcellulose disks (white dotted line) (b). A-C: Sera at the designated time points; D: sera incubated in vitro with bevacizumab
(500 μg/ml final concentration); E: supernatant of leukapheresis products; F: freezing medium including 10% DMSO and 33% RPMI cell culture medium.
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we analyzed sVEGFR1 concentrations in leukapheresis
products. (s)VEGFR1 protein concentrations in supernatant
(108 pg/ml) and cell lysate (136 pg/mg total protein) of
leukapheresis products were comparable to values measured
in PBMCs (73 pg/mg total protein) from other donors, but
significantly lower than concentrations found in cell lysates
and supernatants of human umbilical vein endothelial cells
(HUVECs) in culture (2232 pg/mg total protein and 2081
pg/ml, respectively). Because CD34+ cells have been reported
to express VEGFR1 (32), we sorted cells from leukapheresis
products for CD34 and VEGFR1 expression by MACS.
CD34+ cells expressed significantly less VEGFR1 than cells
sorted for VEGFR1 expression (Figure 4a).
VEGFR1+ cells in leukapheresis products predominantly
express mRNA encoding for sVEGFR1. RT-qPCR for the
mRNAs of soluble sVEGFR1 and transmembrane VEGFR1 in
cells from leukapheresis products demonstrated that the
sVEGFR1:VEGFR1 mRNA ratio in the VEGFR1+ cell
fraction  was 34:1, compared to a ratio of between 2:1 and 8:1
in CD34+, CD34–, and VEGFR1– cells and cultured HUVECs
(Figure 4b). 
Neutrophilic granulocytes are the most abundant cell
population in leukapheresis products and in the VEGFR-1+
cell fraction of leukapheresis products. To determine the cell
type predominantly expressing VEGFR1 in leukapheresis
products, we quantified leukocyte subpopulations in
leukapheresis products and VEGFR1+, VEGFR1–, CD34+, and
CD34– sorted cells from leukapheresis products using an
automated blood cell analyzer. Neutrophils were the
predominant cells within leukapheresis products. They were
not only predominantly found in the VEGFR-1+ sorted cell
fraction of leukapheresis products, but were also the only cell
type to show a significant difference in number compared to
the VEGFR-1– sorted cell fraction (Figure 5a). These results
were confirmed by Giemsa staining of the cytospin of the
sorted cells, where the VEGFR1+ population mainly consisted
of damaged cells appearing as shadow nuclei of the decaying
fragile neutrophilic granulocytes (not shown).
Flow cytometric analysis of leukapheresis products, CD34+,
CD34–, VEGFR1+, and VEGFR1– sorted cells confirmed that
CD34+ cells were mainly VEGFR1–, except for a small
subpopulation, possibly representing endothelial progenitor
cells (33). VEGFR1+ sorted cells unsurprisingly showed the
Figure 3. Correlation between percentage changes in plasma VEGFR1 concentrations and the pro-/antiangiogenic effects in the CAM of the corresponding
sera from seven patients at four different time points (n=28; note that some dots overlap and may not be distinguished well from each other).
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most uniform VEGFR1+ peak. However, VEGFR1+ cells were
also found in the VEGFR1– sorted cell fraction (Figure 5b-f). 
The neutrophilic granulocyte-gated cells showed the same
pattern of VEGFR1 expression as the whole-cell fraction
positively or negatively sorted for VEGFR1, further
corroborating the finding that VEGFR1+ cells in leukapheresis
products were predominantly neutrophilic granulocytes
(Figure 5g). Although the decrease in VEGFR1 plasma
concentrations was paralleled by a decrease in neutrophilic
granulocytes of 37% in the blood of patients after HDC, the
changes in neutrophilic granulocytes at the different time
points were not statistically significant (not shown).
Discussion
The effects of HDC and ASCT on angiogenesis have not yet
been studied. In this study, we demonstrate that sVEGFR1, a
strong endogenous inhibitor of VEGF activity, is found at high
concentrations in leukapheresis products and in serum of patients
after ASCT, and changes in VEGFR1 plasma concentrations
correlate with the inhibitory effect on angiogenesis on the CAM.
The cells most abundantly expressing VEGFR1 in leukapheresis
products are neutrophils and in these cells, VEGFR1 mRNA
splicing is shifted toward the expression of the soluble isoform.
While several endogenous inhibitors of angiogenesis (20)
exist, VEGFR1 and its soluble isoform sVEGFR1 are among
the strongest endogenous inhibitors of angiogenesis, acting
directly on VEGF via sequestration of circulating VEGF and
through a dominant negative effect by forming heterodimers
with VEGFR1 and -2 (29). PGF has been shown to act as an
amplifier of VEGF-driven angiogenesis (24). The changes in
plasma VEGFR1 in our study, together with the finding that
plasma VEGF is unchanged before and after HDC, and
ASCT, respectively, and a lack of PGF increase after ASCT
are consistent with a proangiogenic pattern after HDC, and
an antiangiogenic pattern after ASCT. Tachi et al. observed
an increase in VEGF serum levels over 3 months after bone-
marrow mononuclear cell implantation for critical severe
limb ischemia (14), while Sasaki et al. reported a decrease
of proangiogenic factors in a patient with multiple myeloma
following chemotherapy and peripheral ASCT (18).
Interestingly, an increase in bone marrow endothelial
colonies after HDC, and a significant reduction of their
number after ASCT was observed in non-Hodgkin’s
lymphoma patients, corroborating an antiangiogenic response
of ASCT also on a cellular level (16). A decrease in
microvessel density after ASCT has been described in
multiple myeloma (17) although this finding is not consistent
(34). The source of sVEGFR1 in the blood of patients after
Figure 4. Enzyme-linked immunosorbent assay of (s)VEGFR1 in whole leukapheresis products (apheresate) and in CD34 and VEGFR1 positively and
negatively selected cells from apheresis products, respectively, compared to peripheral blood mononuclear cells (PBMC) and human umbilical vein
endothelial cells (HUVEC) (a). *p<0.05. mRNA expression of the alternatively spliced variants of VEGFR1 (i.e. the soluble sVEGFR1 and the
transmembrane VEGFR1) in VEGFR1 positively selected cells from apheresis products (b). n=4 for each experiment (mean±SEM).

ht
tp
://
do
c.
re
ro
.c
h
Figure 5. a: Automated blood cell analysis of leukocyte subfractions within leukapheresis products. n=4 (mean±SEM). *p<0.05. Flow cytometric analysis
of a leukapheresis product (b), CD34+ (c), CD34– (d), VEGFR1+ (e), and VEGFR1– (f) magnetic activated sorted cells. g: Percentage of VEGFR-1+
cells in all cells vs. cells gated for neutrophilic granulocytes in leukapheresis products are shown. n=4 (mean±SEM). *p<0.05.
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ASCT for ischemic disease has been attributed to endothelial
progenitor cells, which have been demonstrated to be
increased after chemotherapy (33, 35) and ASCT (15).
However, in our experience the CD34+ cell fraction
(including endothelial progenitor cells) may be as low as 1-
2% of all cells within the leukapheresis product, if no CD34+
enrichment procedure is performed, and one may wonder
therefore if it is a major source of sVEGFR1.
Stimulation of angiogenesis after HDC is not an unexpected
finding, as recent studies reported changes consistent with an
angiogenic switch after cytotoxic systemic chemotherapy (35,
36). There are only few clinical studies addressing the
functional effects of ASCT on angiogenesis. Most studies have
been performed in patients with ischemic digits or limbs due
to connective tissue or vascular disease, and in patients with
cardiac ischemic disease. Functional outcomes in these studies
were measured by angiography, and variable rates of improved
perfusion were reported, which can be considered a
proangiogenic effect, or more precisely, vascular remodeling
and arteriogenesis (6-8). However, the methods of autologous
stem cell collection were considerably heterogenous in such
studies, using only positively selected CD34+ cells from
peripheral leukapheresis after recombinant human G-CSF with
(13) or without (37) previous cyclophosphamide as a
mobilization regimen, using mononuclear cells from bone
marrow aspirate that contain only 0.5% CD34+ cells (10), or
using recombinant human G-CSF-stimulated cells from direct
bone marrow aspiration without further processing (11).
Furthermore, there are no functional data on the potentially
distinct effect of the co-infused non-cellular components of the
leukapheresis product on angiogenesis. It is possible that
cellular and non-cellular components of leukapheresis products
have distinct and maybe even opposing effects on angiogenesis.
There are several explanations for the proangiogenic effect
of serum from patients before HDC. All patients in our study
received a cytotoxic chemotherapy and recombinant human
G-CSF for stem cell mobilization shortly before ASCT,
either as a previous chemotherapy cycle or as a separate
regimen in patients with multiple myeloma. Chemotherapy
itself could therefore be the cause of increased angiogenesis.
However, given that all of our patients undergoing
HDC/ASCT suffered from active cancer, the stimulatory
effect of serum on CAM angiogenesis before HDC might
also be explained, by tumors eliciting proangiogenic
responses (35, 36). G-CSF has been shown to promote
angiogenesis (38) via the release of VEGF from neutrophils
(39). Interestingly, however, the administration of
recombinant human G-CSF did not result in a proangiogenic
response to serum in the CAM assay in the six out of seven
patients receiving it from the day before ASCT until
hematological reconstitution (40). 
Leukapheresis products contained high concentrations of
sVEGFR1. To our surprise, the cells expressing the highest
concentrations of VEGFR1 in leukapheresis products were not
CD34+ cells. Lysates of VEGFR1 positively selected cells
expressed almost 5 times more VEGFR1 than CD34 positively
selected cells, while the expression of VEGFR1 was not
significantly different between CD34 positively and VEGFR1
negatively selected cells. VEGFR1 is expressed on many
different cell types, including neutrophils (25-27, 32, 41-44).
VEGF-dependent neutrophil migration has been demonstrated
to be mediated by VEGFR1, in analogy to similar findings in
monocytes (26, 42). For monocytes it has been shown that
GM-CSF-induced sVEGFR1 expression inhibits angiogenesis
(45). Given the abundance of neutrophils in leukapheresis
products in our study, it seems likely that neutrophils are a
major source of VEGFR1 after ASCT. In our study,
neutrophils were the most abundant cell type in leukapheresis
products, and only neutrophils showed a significant difference
in number when leukapheresis products were positively and
negatively selected for VEGFR1-expressing cells, further
corroborating that overall, this cell type is the predominant cell
type expressing VEGFR1.
However, the sole expression of transmembrane VEGFR1
by neutrophils does not yet explain the increase in soluble
plasma sVEGFR. We speculated that a cell type, which
predominantly expresses VEGFR1 would also be a major
source of sVEGFR1, if the mRNA ratio of the differentially
spliced isoforms sVEGFR1:VEGFR1 was not smaller than that
of other VEGFR1-expressing cell types. In our study, the
mRNA ratio of the differentially spliced isoforms
sVEGFR1:VEGFR1 showed a shift in favor of the expression
of sVEGFR1 in VEGFR1 positively selected cells, which we
have demonstrated to consist mainly of neutrophils. Indeed, a
reciprocal relationship of sVEGFR1 and VEGFR1 has been
proposed for the modulation of responsiveness to VEGF in
monocytes and neutrophils (26, 46). 
Using flow cytometric analysis, we confirmed that CD34+
sorted cells are mainly VEGFR1–, with only a small
population expressing VEGFR1. As CD34+ cells have been
shown to express VEGFR1 (32), the small fraction of
VEGFR1+ CD34 positively sorted cells was unexpected, but
might represent endothelial progenitor cells (33).
While VEGFR1+ sorted cells naturally exhibited a strong
and uniform VEGFR1+ peak, VEGFR1 negatively sorted cells
also exhibited a VEGFR-1+ peak, albeit smaller. This can be
technically explained by the possibility that VEGFR1 may be
a weaker epitope for magnetic cell sorting, resulting in
contamination of the VEGFR1– flow-through. When the cells
were analyzed according to their typical scatter pattern
(granulocyte gate), virtually all VEGFR1+ cells proved to be
granulocytes. The results of cytologic and automated cell
analysis confirmed the expected distribution, with >90% of the
granulocyte population being neutrophilic granulocytes.
In conclusion, the efficiency of HDC followed by ASCT is
believed to result from the fact that due to the re-infusion of bone
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marrow stem cells, the time to hematologic recovery can be
shortened and chemotherapy can be applied at higher doses than
hematologic toxicity resulting in prolonged aplasia and
associated morbidity and mortality would normally allow. In this
study, we provide evidence that ASCT after HDC can exert an
antiangiogenic effect, possibly mediated via VEGFR1 derived
from neutrophils in the leukapheresis product. Although a
number of other factors, which have not yet been explored, could
contribute to the antiangiogenic effects observed, our findings
could have important implications for manipulative strategies in
ASCT, e.g. CD34+ enrichment by purging. Consequently,
application of neutrophil depletion techniques might result in a
diminished beneficial antiangiogenic effect. Given the
differences in the methodology of stem cell collection, a better
understanding of the heterogeneity regarding the composition of
leukapheresis products might explain the sometimes
contradictory results in therapeutic angiogenesis and could help
improving the outcome of ASCT in the treatment of hematologic
and oncologic malignancy and ischemic disease.
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